Three out of four patients with the cancerous forms of gestational trophoblastic disease (GTD) went into remission after receiving the immunotherapy drug pembrolizumab in a clinical trial, report researchers. The trial is the first to show that pembrolizumab can be used to successfully treat women with GTD.